The company’s latest pump includes a predictive low glucose suspend feature designed to reduce the frequency and duration of hypoglycemia.
Using the Basal-IQ algorithm, the system predicts where a user’s blood sugar levels are heading up to 30 minutes into the future. When the algorithm predicts low glucose levels, the device suspends insulin delivery and automatically resumes once glucose levels begin to rise, according to Tandem.
Customers that are using older versions of Tandem’s t:slim X2 pump have the option to add the Basal-IQ technology via a remote software update. Tandem said it expects to begin shipping its latest generation of pumps by the end of August.
“This launch marks the achievement of our goal to offer people with diabetes a simple-to-use automated insulin delivery feature that can reduce time spent low without adding significant burden to the pump therapy experience,” president & CEO Kim Blickenstaff said in prepared remarks. “Our ability to provide remote software updates, allowing in-warranty t:slim X2 Pump users the ability to add Basal-IQ Technology to their current pumps using a personal computer, is unparalleled in the industry and further differentiates the t:slim X2 Insulin Pump from other devices on the market.”
Tandem won FDA approval for the t:slim X2 pump with Basal-IQ tech in June this year.
Heidi Dohse was diagnosed with a rare arrhythmia in 1982 and has been 100% pacemaker dependent for over 30 years. With the help of wearable devices, she has been able to pursue her dream to become a competitive cyclist.
You can hear her story and more when you register for DeviceTalks Boston, October 8-10.
Use code FINISHLINE to save an additional 10%.